Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1518-2025

FilmArra Pneumonia Panel plus (Pneumoplus), REF: RFIT-LBL-0374 Recall

FilmArra Pneumonia Panel plus (Pneumoplus), REF: RFIT-LBL-0374

FDA recall Class II

Ongoing

FDA lists this Class II recall for FilmArra Pneumonia Panel plus (Pneumoplus), REF: RFIT-LBL-0374. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1518-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Feb 27, 2025
FDA report date
Apr 16, 2025
Quantity in commerce
29 kits
Distribution
See key details
FDA cause
Nonconforming Material/Component

What is being recalled?

FilmArra Pneumonia Panel plus (Pneumoplus), REF: RFIT-LBL-0374

Affected model & UDI checker

Search the exact identifiers published for Z-1518-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
RFIT-LBL-0374FilmArra Pneumonia Panel plus (Pneumoplus), REF: RFIT-LBL-0374Check source noticeNot specified
Not specifiedFilmArra Pneumonia Panel plus (Pneumoplus), REF: RFIT-LBL-0374Check source notice00815381020314
FDA code information

UDI: 00815381020314/Lot# 0979424

View the original FDA recall notice

Why was this product recalled?

Increased risk of control failures and false negative test results with multiplexed nucleic acid test.

What actions did Biofire Diagnostics, LLC take?

On February 28, 2025, Biomerieux issued an "Urgent Field Safety Notice" Recall notification to affected consignees via email. The notice described the product, problem and actions to be taken. Biomerieux asked consignees to take the following actions: " Immediately examine your inventory for the lot identified in this field safety notice. " Discontinue use and discard any remaining product from this lot in your possession. bioMrieux will replace the product at no charge in accordance with our standard limited warranty. " Confirm the amount of pouches scrapped (if any) on the attached Acknowledgement of Receipt Form. " If you have further distributed this product, please identify any recipients and notify them at once. " Please complete the accompanying Acknowledgement of Receipt Form and return to bioMrieux so that bioMrieux may acknowledge your receipt of this notification. If you require additional assistance or have any questions, please contact your local bioMrieux Customer Service representative or call customer service department at 1-800-736-6354.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology